Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in Sickle Cell Disease Treatment: A Comparative Review of Hematopoietic Stem Cell Transplantation and Gene Therapy (Casgevy and Lyfgenia)

1 Sept 2025

Abstract excerpt

Sickle cell disease (SCD), affecting approximately 2.1% of Bahrain's population, is a prevalent inherited disorder that necessitates effective treatments and long-term management. This review highlights two innovative gene therapies (Casgevy and Lyfgenia) and compares their efficacy and safety with hematopoietic stem cell transplantation (HSCT)-the only curative option currently available for SCD. While HSCT...

Topics

Join the communities discussing this publication.

Hemoglobinopathies and Related Disorders
Parvovirus B19 Infection Studies
Prenatal Screening and Diagnostics

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40757789
DOI: 10.1177/15473287251362882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in Sickle Cell Disease Treatment: A Comparative Review of Hematopoietic Stem Cell Transplantation and Gene Therapy (Casgevy and Lyfgenia)PMID 40757789Read ↗

Stem cell transplantation in sickle cell disease: therapeutic potential and challenges facedSemantic proximity Read ↗

Sickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approachesSemantic proximity Read ↗

Current state of gene therapy in sickle cell diseaseSemantic proximity Read ↗

Gene therapy for sickle cell disease: where we are now?Semantic proximity Read ↗

Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access ChallengesSemantic proximity Read ↗

Treating Sickle Cell Disease: Gene Therapy ApproachesSemantic proximity Read ↗

Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene EditingSemantic proximity Read ↗

Current and emerging treatments for sickle cell diseaseSemantic proximity Read ↗

The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challengesSemantic proximity Read ↗

Recent advancements in gene therapy for sickle cell disease and β-thalassemiaSemantic proximity Read ↗

Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapySemantic proximity Read ↗

Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive CrisesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.